Results of a new clinical trial published in Nature Medicine show that a novel, personalized neoantigen vaccine therapy demonstrated promising anti-tumor effica
Stay updated with breaking news from Davidb Weiner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results of a new clinical trial published in Nature Medicine show that a novel, personalized neoantigen vaccine therapy demonstrated promising anti-tumor effica
Results of a new clinical trial published in Nature Medicine show that a novel, personalized neoantigen vaccine therapy demonstrated promising anti-tumor effica
<p>Wistar’s David B. Weiner, Ph.D., and collaborators, have engineered novel monoclonal antibodies that engage Natural Killer cells through a unique surface receptor that activates the immune system to fight against cancer. </p>
Novel human Siglec-7 monoclonal and bispecific antibodies are being developed as potential future cancer immunotherapies...
Bank of America cut shares of Inovio Pharmaceuticals (NASDAQ:INO – Get Rating) from a neutral rating to an underperform rating in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage currently has $2.00 price objective on the biopharmaceutical company’s stock. INO has been the topic of several other research reports. Royal […]